Company intelligence / Profile preview
RasCal Therapeutics
Palo Alto, California, United States
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
RasCal Therapeutics is conducting a Phase 1a/1b clinical trial of its lead compound, RSC-1255, in patients with advanced solid tumor malignancies. The study aims to determine the appropriate dose and assess safety and preliminary efficacy in patients who have failed or are intolerant to standard therapies. No published clinical results are available as of June 2025.
- Therapeutic areas
- GastroenterologyOncologyEndocrinologyNeurology
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.
Beyond the preview
Go deeper on RasCal Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RasCal Therapeutics.